Coronavirus (Covid-19) Health Alert
A company, business, organisation, or institution can purchase rapid antigen self-tests for their workers to use at home or on site.
It is important that any business considering implementing rapid antigen testing takes into consideration the implications of testing in these environments, including:
- processes to maintain confidentiality of patient information
- a procedure for possible closure of the business and isolation of staff if a positive result is received from a rapid antigen test, and
- any state and territory directions around rapid antigen testing, including reminding individuals who test positive that they may be legally required to report a positive test result to their state or territory health department.
Businesses or organisations wanting to implement rapid antigen point of care testing and even self-testing of their workers should refer to the additional guidance on our website that provides further information on what processes and protocols you need to have in place to safely conduct testing in your work place.
Businesses that choose to use a Covid-19 rapid self-test do not need to comply with the requirements for supervision of testing. However other general information included in this guidance such as test choice, test performance and safe implementation of testing, is still applicable when considering how to implement rapid antigen testing.
Different state and territory jurisdictions may have differing testing requirements for essential workers, based on their public health orders. Please contact the relevant state or territory government or see their websites for how often mandatory tests are required.
A sponsor can authorise a distributor to supply the rapid antigen self-tests on their behalf. This is usually via a contractual arrangement between the sponsor and distributor. A distributor is acting on behalf of the sponsor and can only supply the device in accordance with the conditions. A distributor must also maintain records relating to all supply of rapid antigen self-tests and be able to provide this information to the sponsor. The sponsor remains responsible for supply of the device and all post-market monitoring and reporting responsibilities.
For more information, refer to the following resources: